GTBP vs. PTPI, CLVR, ARTL, LIPO, ZVSA, CPHI, SNGX, KZIA, LGVN, and XCUR
Should you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Petros Pharmaceuticals (PTPI), Clever Leaves (CLVR), Artelo Biosciences (ARTL), Lipella Pharmaceuticals (LIPO), ZyVersa Therapeutics (ZVSA), China Pharma (CPHI), Soligenix (SNGX), Kazia Therapeutics (KZIA), Longeveron (LGVN), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry.
GT Biopharma (NASDAQ:GTBP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
In the previous week, GT Biopharma had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 7 mentions for GT Biopharma and 6 mentions for Petros Pharmaceuticals. GT Biopharma's average media sentiment score of 0.78 beat Petros Pharmaceuticals' score of -0.27 indicating that GT Biopharma is being referred to more favorably in the media.
GT Biopharma has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
GT Biopharma has a net margin of 0.00% compared to Petros Pharmaceuticals' net margin of -181.87%. Petros Pharmaceuticals' return on equity of -68.90% beat GT Biopharma's return on equity.
GT Biopharma presently has a consensus target price of $150.00, indicating a potential upside of 4,501.23%. Petros Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 629.79%. Given GT Biopharma's higher possible upside, equities research analysts plainly believe GT Biopharma is more favorable than Petros Pharmaceuticals.
8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 10.0% of GT Biopharma shares are owned by insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
GT Biopharma has higher earnings, but lower revenue than Petros Pharmaceuticals. GT Biopharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
GT Biopharma received 114 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 62.84% of users gave GT Biopharma an outperform vote.
Summary
Petros Pharmaceuticals beats GT Biopharma on 9 of the 15 factors compared between the two stocks.
Get GT Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GT Biopharma Competitors List
Related Companies and Tools
